Cambridge Nutritional Sciences plc
(the 'Company' or 'CNS')
Omega Diagnostics Summons Update
Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, today provides an update in relation to the summons for its subsidiary Omega Diagnostics Limited ("ODL") regarding a historical breach of Health & Safety regulations arising from the facility used by Omega South West, which ODL sold in 2018. Further details of the summons were disclosed in the Company's announcement of 21 January 2025.
Further to the summons, ODL appeared in Exeter Magistrates Court yesterday and entered a guilty plea to all charges. It was confirmed that the sentencing hearing is to be held on 22 May 2025.
As noted previously, the facility in question was sold in 2018 and in the same year Omega South West ceased all trading activities. This entity has not formed any part of the Company's ongoing operations or business model and there are currently no employees within the Company who had any dealings or involvement with Omega South West.
Further announcements will be made as and when appropriate.
Contacts:
| Cambridge Nutritional Sciences plc | |||
| Carolyn Rand, Non-Executive Chair | | ||
| James Cooper, Interim Chief Executive | | ||
| | | ||
| Cavendish Capital Markets Limited | Tel: 020 7220 0500 | ||
| Geoff Nash / Edward Whiley (Corporate Finance) | | ||
| Nigel Birks / Harriet Ward (ECM) | | ||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
